唾液酸类标志物在肿瘤发生发展中的研究进展

doi:10.3969/j.issn.1673-8640.2020.12.025

摘要/Abstract

摘要：

在肿瘤的发生、发展中,唾液酸转移酶的异常表达可调节肿瘤细胞的生物学特性。异常唾液酸化可增强肿瘤细胞的黏附转移能力及对化疗药物的抗性。唾液酸转移酶的异常表达还与肿瘤转移的组织器官特异性有关。异常结构唾液酸修饰的糖蛋白在肿瘤的早期诊断和预后评价中有重要价值,使寻找新型肿瘤标志物成为可能。文章介绍了近年来唾液酸化影响肿瘤发生、发展的相关机制,以及血清唾液酸类标志物在肿瘤诊断和预后中的价值。

关键词: 唾液酸化, 唾液酸转移酶, 肿瘤

Abstract:

In the occurrence and development of tumors,the abnormal expression of sialyltransferase can regulate the biological characteristics of tumor cells. Abnormal sialylation can enhance the adhesion and metastasis ability of tumor cells,and can enhance tumor resistance to chemotherapy drugs. The abnormal expression of sialyltransferase is also related to the tissue and organ specificity of tumor metastasis. Sialic acid-modified glycoproteins with abnormal structures are of value in the early diagnosis and prognostic evaluation of tumors,which makes it possible to find new tumor markers. This review introduces the related mechanisms of sialylation affecting tumor occurrence and development in the recent years and the role of serum sialic acid markers in tumor diagnosis and prognosis.

Key words: Sialylation, Sialyltransferase, Tumor

中图分类号:

R446.1

别立翰, 房萌, 陆志成, 高春芳. 唾液酸类标志物在肿瘤发生发展中的研究进展[J]. 检验医学, 2020, 35(12): 1304-1309.

BIE Lihan, FANG Meng, LU Zhicheng, GAO Chunfang. Research progress of sialic acid markers in tumor occurrence and development[J]. Laboratory Medicine, 2020, 35(12): 1304-1309.

参考文献 48

[1]	MEREITER S,BALMAÑA M,CAMPOS D,et al. Glycosylation in the era of cancer-targeted therapy:where are we heading?[J]. Cancer Cell,2019,36(1):6-16.
[2]	LI F,DING J.Sialylation is involved in cell fate decision during development,reprogramming and cancer progression[J]. Protein Cell,2019,10(8):550-565.
[3]	COHEN M,VARKI A .The sialome-far more than the sum of its parts[J]. OMICS,2010,14(4):455-464.
[4]	SCHAUER R,KAMERLING J P .Exploration of the sialic acid world[J]. Adv Carbohydr Chem Biochem,2018,75:1-213.
[5]	PEARCE O M,LÄUBLI H. Sialic acids in cancer biology and immunity[J]. Glycobiology,2016,26(2):111-128.
[6]	WATERS P J,LEWRY E,PENNOCK C A .Measurement of sialic acid in serum and urine:clinical applications and limitations[J]. Ann Clin Biochem,1992,29(Pt6):625-637.
[7]	TESHIMA S,TAMAI K,HAYASHI Y,et al.New enzymatic determination of sialic acid in serum[J]. Clin Chem,1988,34(11):2291-2294.
[8]	HORIUCHI T,KUROKAWA T.New enzymatic endpoint assay of serum sialic acid[J]. Clin Chim Acta,1989,182(1):117-121.
[9]	KRISHNAN K,BALASUNDARAM S. Evaluation of total and lipid bound sialic acid in serum in oral leukoplakia[J]. J Clin Diagn Res,2017,11(3):ZC25-ZC27.
[10]	TEWARSON S L,MITTAL V P,SINGH M,et al.Serum sialic acid-an important cancer marker[J]. Indian J Cancer,1993,30(3):125-131.
[11]	RAJENDIRAN K S,ANANTHANARAYANAN P H,SATHEESH S,et al.Elevated levels of serum sialic acid and high-sensitivity C-reactive protein:markers of systemic inflammation in patients with chronic heart failure[J]. Br J Biomed Sci,2014,71(1):29-32.
[12]	CANDIDO J,HAGEMANN T.Cancer-related inflammation[J]. J Clin Immunol,2013,33(Suppl 1):79-84.
[13]	DE GRAAF T W,VAN DER STELT M E,ANBERGEN M G,et al. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein(orosomucoid) in human sera[J]. J Exp Med,1993,177(3):657-666.
[14]	邢卉春. 甲胎蛋白异质体检测在原发性肝癌诊疗中的价值[J]. 中华检验医学杂志,2013,36(2):123-124.
[15]	OHYAMA C,HOSONO M,NITTA K,et al.Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy[J]. Glycobiology,2004,14(8):671-679.
[16]	ISHIKAWA T,YONEYAMA T,TOBISAWA Y,et al.An automated micro-total immunoassay system for measuring cancer-associated α2,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis[J]. Int J Mol Sci,2017,18(2):470.
[17]	POON T C W,MOK T S K,CHAN A T C,et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein[J]. Clin Chem,2002,48(7):1021-1027.
[18]	ANG I L,POON T C W,LAI P B S,et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma:a glycoproteomic approach[J]. J Proteome Res,2006,5(10):2691-2700.
[19]	ZHANG Z,WUHRER M,HOLST S.Serum sialylation changes in cancer[J]. Glycoconj J,2018,35(2):139-160.
[20]	ZENG P,LI H,CHEN Y,et al.Serum CA199 levels are significantly increased in patients suffering from liver,lung,and other diseases[J]. Prog Mol Biol Transl Sci,2019,162:253-264.
[21]	LAN Y,HAO C,ZENG X,et al.Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers[J]. Am J Cancer Res,2016,6(11):2390-2415.
[22]	SALDOVA R,ROYLE L,RADCLIFFE C M,et al.Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG[J]. Glycobiology,2007,17(12):1344-1356.
[23]	MUNKLEY J .The role of sialyl-Tn in cancer[J]. Int J Mol Sci,2016,17(3):275.
[24]	KRISHN S R,KAUR S,SMITH L M,et al.Mucins and associated glycan signatures in colon adenoma-carcinoma sequence:prospective pathological implication(s) for early diagnosis of colon cancer[J]. Cancer Lett,2016,374(2):304-314.
[25]	SUNG P L,WEN K C,HORNG H C,et al.The role of α2,3-linked sialylation on clear cell type epithelial ovarian cancer[J]. Taiwan J Obstet Gynecol,2018,57(2):255-263.
[26]	WU H,SHI X L,ZHANG H J,et al.Overexpression of ST3Gal-Ⅰ promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma[J]. Onco Targets Ther,2016,9:2227-2236.
[27]	CUI H X,WANG H,WANG Y,et al.ST3Gal Ⅲ modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules[J].Oncol Rep,2016,36(6):3317-3324.
[28]	MAJURI M L,NIEMELÄ R,TIISALA S,et al.Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines:role in synthesis of E-selectin counter-receptors[J]. Int J Cancer,1995,63(4):551-559.
[29]	PÉREZ-GARAY M,ARTETA B,LLOP E,et al. α2,3-sialyltransferase ST3Gal Ⅳ promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues[J]. Int J Biochem Cell Biol,2013,45(8):1748-1757.
[30]	SHEN L,LUO Z,WU J,et al.Enhanced expression of α2,3-linked sialic acids promotes gastric cancer cell metastasis and correlates with poor prognosis[J]. Int J Oncol,2017,50(4):1201-1210.
[31]	YOSHIHAMA N,YAMAGUCHI K,CHIGITA S,et al.A novel function of CD82/KAI1 in sialyl Lewis antigen-mediated adhesion of cancer cells:evidence for an anti-metastasis effect by down-regulation of sialyl lewis antigens[J]. PLoS One,2015,10(4):e0124743.
[32]	CHUNG T W,KIM S J,CHOI H J,et al.Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis[J]. Mol Cancer,2014,13:222.
[33]	GARNHAM R,SCOTT E,LIVERMORE K E,et al.ST6GAL1:a key player in cancer[J]. Oncol Lett,2019,18(2):983-989.
[34]	SWINDALL A F,BELLIS S L.Sialylation of the fas death receptor by ST6Gal-I provides protection against fas-mediated apoptosis in colon carcinoma cells[J]. J Biol Chem,2011,286(26):22982-22990.
[35]	IMAMAKI R,OGAWA K,KIZUKA Y,et al.Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis[J]. Oncogene,2018,37(31):4287-4299.
[36]	HAN Y,LIU Y,FU X,et al.miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1[J]. J Physiol Biochem,2018,74(3):491-501.
[37]	BRITAIN C M,HOLDBROOKS A T,ANDERSON J C,et al.Sialylation of EGFR by the ST6Gal-Ⅰ sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death[J]. J Ovarian Res,2018,11(1):12.
[38]	CHANG T C,CHIN Y T,NANA A W,et al.Enhancement by nano-diamino-tetrac of antiproliferative action of gefitinib on colorectal cancer cells:mediation by EGFR sialylation and PI3K activation[J]. Horm Cancer,2018,9(6):420-432.
[39]	LIU N,ZHU M,LINHAI Y,et al.Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways[J]. Oncol Rep,2018,40(5):2997-3005.
[40]	OGAWA T,HIROHASHI Y,MURAI A,et al.ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway[J]. Oncotarget,2017,8(68):112550-112564.
[41]	LIU B,LIU Y,ZHAO L,et al.Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway[J]. Mol Carcinog,2017,56(12):2669-2680.
[42]	MUNKLEY J,OLTEAN S,VODÁK D,et al. The androgen receptor controls expression of the cancer- associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer[J]. Oncotarget,2015,6(33):34358-34374.
[43]	BOS P D,ZHANG X H,NADAL C,et al.Genes that mediate breast cancer metastasis to the brain[J]. Nature,2009,459(7249):1005-1009.
[44]	FALCONER R A,ERRINGTON R J,SHNYDER S D,et al.Polysialyltransferase:a new target in metastatic cancer[J]. Curr Cancer Drug Targets,2012,12(8):925-939.
[45]	GONG L,ZHOU X,YANG J,et al.Effects of the regulation of polysialyltransferase ST8SiaⅡ on the invasiveness and metastasis of small cell lung cancer cells[J]. Oncol Rep,2017,37(1):131-138.
[46]	LIU J,ZHENG X,PANG X,et al.Ganglioside GD3 synthase(GD3S),a novel cancer drug target[J]. Acta Pharm Sin B,2018,8(5):713-720.
[47]	NGUYEN K,YAN Y,YUAN B,et al.ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway[J]. Mol Cancer Ther,2018,17(12):2689-2701.
[48]	BOBOWSKI M,VINCENT A,STEENACKERS A,et al.Estradiol represses the G(D3),synthase gene,ST8SIA1,expression in human breast cancer cells by preventing NFκB binding to,ST8SIA1,promoter[J]. PLoS One,2013,8(4):e62559.